The aim of this study is to investigate the effectiveness of virtual reality exercises onpain, cardiopulmonary capacity, mood and quality of life in patients with post-COVIDsyndrome.

The main objectives of ECCO-2 are: 1) Efficacy: to study whether EQUINACEA ARKOPHARMA,hard caplets containing cryogenized root of the plant Echinacea purpurea, show animprovement of the clinical manifestations and disease course in ambulatory patients withcovid-19 with a respiratory presentation and not requiring hospitalization (i.e., mildcovid-19). The drug being evaluated will be added as a supplement of the standardtreatment, with its current recommended dose for treatment of the common cold. 2) Safety:to determine that the incidence of adverse events is not higher than that seen with thestandard treatment applied in each case.

The XPHI-COVID-2 randomized study aims to investigate the moral choices in a context ofscarce resources.The participants are asked to complete the questionnaire of the Oxford UtilitarianismScale and are exposed to medical triage dilemmas.Participants are randomized between a group with reading of ethical guidelines and agroup without reading of ethical guidelines, before they are asked to complete thequestionnaire and being exposed to triage dilemmas.

This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65years who have received three doses of mRNA vaccine will be randomized to vaccinationwith a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine or to vaccination with acontrol (Prevnar-13 vaccine).

SOLIDARITY Finland Long-COVID trial assesses the effects of remdesivir + standard of care(SoC) vs. only SoC on long-COVID symptoms and quality of life (QoL) using questionnairesat one and two years post-discharge.Objectives i) Long-COVID symptoms - To investigate the effect of remdesivir (vs. SoC) on the occurrence of symptoms that have been associated with the long-COVID syndrome. The questionnaires will take place 1 and 2 years after the hospital admission. - The symptom questionnaire - that will be completed by patients at one and two years - measures basic patient information (age, height, weight, smoking status, major comorbidity, and working status) and a wide variety of potential long-COVID-symptoms and their bother (1. Fatigue; 2. Attention deficits; 3. Memory problems; 4. Sleeping difficulties; 5. Depressive mood; 6. Anxiety; 7. Dizziness; 8. Headache; 9. Tinnitus; 10. Paresthesias; 11. Changes in taste/smell perceptions; 12. Postexertional malaise; 13. Palpitations; 14. Chest discomfort; 15. Nausea; 16. Skin rash; 17. Joint aches; 18. Muscle pains; 19. Continuous cough; 20. Respiratory tract mucous discharges) in remdesivir and usual care armsii) Quality of life - EQ-VAS: to compare patients' quality of life in remdesivir and usual care arms. - EQ-5D-5L questionnaire assesses the following domains: 1. Mobility; 2. Self-care; 3. Usual activities; 4. Pain and discomfort; 5. Anxiety and depression; 6. The VAS of subjective perception of overall health.Additionally (at 1 or 2 years; depending on future funding and ethical approvaldecisions; currently the study has ethical approval for long-COVID and quality of lifeassessments only): - The Finnish healthcare registries (Statistics Finland Mortality Database and the HILMO Care Register for Health Care) will be used to estimate long-term mortality and incidence of major comorbidity in remdesivir and usual care arms - Lung function will be assessed using spirometry and diffusing capacity, as well as the six-minute walk test (6 mwt) in remdesivir and usual care arms - Whole-genome genotyping will be performed for a genome-wide association study to investigate genetic correlates of long-COVID-19 -symptoms in remdesivir and usual care armsUPDATE 02.02.2022:Primary outcomes will comprise the following: 1. EQ-VAS 2. EQ-5D-5L, summary 3. Does the patient feel recovered from COVID-19-infection at one year or not? (question no. 10) 4. Fatigue (questionnaire, question no. 14) 5. Exertional dyspnea (question no. 12)

The aim of the joint project PROVID is to contribute to better outcome prediction forCOVID-19 patients, to better clinical management, and to the development of newtherapies. To this end, the investigators will collect detailed data on the course ofCOVID-19 patients and deeply characterize them at the molecular level. The investigatorsalso aim to identify compounds with the potential to improve outcome.The PROVID-PROGRESS study is being carried out as a prospective, longitudinal,multicenter observational study (case cohort study) with material asservation forgenomic, transcriptomic and proteomic analyzes on adult patients with COVID-19.

The main aim of the study is to estimate the potential efficacy of i.v. canrenone asadd-on therapy on maximal medical treatment versus maximal medical treatment alone intreating moderate-to-severe ARDS due to SARS-CoV-2.

Modelling repurposed from pandemic influenza is currently informing all strategies forSARS-CoV-2 and the disease COVID-19. A customized disease specific understanding will beimportant to understand subsequent disease waves, vaccine development and therapeutics.For this reason, ISARIC (the International Severe Acute Respiratory and EmergingInfection Consortium) was set up in advance. This focuses on hospitalised andconvalescent serum samples to understand severe illness and associated immune response.However, many subjects are seroconverting with mild or even subclinical disease.Information is needed about subclinical infection, the significance of baseline immunestatus and the earliest immune changes that may occur in mild disease to compare withthose of SARS-CoV-2. There is also a need to understand the vulnerability and response toCOVID-19 of the NHS workforce of healthcare workers (HCWs). HCW present a cohort withlikely higher exposure and seroconversion rates than the general population, but who canbe followed up with potential for serial testing enabling an insight into early diseaseand markers of risk for disease severity. We have set up "COVID-19: Healthcare workerBioresource: Immune Protection and Pathogenesis in SARS-CoV-2". This urgent fieldworkaims to secure significant (n=400) sampling of healthcare workers (demographics, swabs,blood sampling) at baseline, and weekly whilst they are well and attending work, withacute sampling (if hospitalised, via ISARIC, if their admission hospital is part of theISARIC network) and convalescent samples post illness. These will be used to addressspecific questions around the impact of baseline immune function, the earliest immuneresponses to infection, and the biology of those who get non-hospitalized disease forlocal research and as a national resource. The proposal links directly with other ongoingISARIC and community COVID projects sampling in children and the older age population.Reasonable estimates suggest the usable window for baseline sampling of NHS HCW isclosing fast (e.g. baseline sampling within 3 weeks).

COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposureprophylaxis (PEP) against on COVID-19 was identified as an urgent research priority bythe WHO, and lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19treatment and PEP, with a good safety profile and global availability. This is a clusterrandomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that willaddress the immediate need for preventive interventions, generate key data on COVID-19transmission, and serve as a research platform for future vaccines and preventive agents.